KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.96

Prevalence of Comorbid Factors in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Randomized Trial of an Oral Microbiota-Based Therapeutic.

Charles S Berenson, Bret Lashner, Louis Y Korman, Elizabeth Hohmann, Abhishek Deshpande, Thomas J Louie, Matthew Sims, Darrell Pardi, Colleen S Kraft, Elaine E L Wang, Stuart H Cohen, Paul Feuerstadt, Caterina Oneto, Bharat Misra, John Pullman, Ananya De, Asli Memisoglu, David A Lombardi, Brooke R Hasson, Barbara H McGovern, Lisa von Moltke, Christine H Lee

Clin Infect Dis 77(11) 1504-1510

PMID37539715
PMCIDPMC10686959
DOI10.1093/cid/ciad448
发表日期2023-08-04
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
摘要

摘要

BACKGROUND: Although comorbidities are risk factors for recurrent Clostridioides difficile infection (rCDI), many clinical trials exclude patients with medical conditions such as malignancy or immunosuppression. In a phase 3, double-blind, placebo-controlled, randomized trial (ECOSPOR III), fecal microbiota spores, live (VOWST, Seres Therapeutics; hereafter "VOS," formerly SER-109), an oral microbiota therapeutic, significantly reduced the risk of rCDI at week 8. We evaluated the efficacy of VOS compared with placebo in patients with comorbidities and other risk factors for rCDI. METHODS: Adults with rCDI were randomized to receive VOS or placebo (4 capsules daily for 3 days) following standard-of-care antibiotics. In this post hoc analysis, the rate of rCDI through week 8 was assessed in VOS-treated participants compared with placebo for subgroups including (i) Charlson comorbidity index (CCI) score category (0, 1-2, 3-4, ≥5); (ii) baseline creatinine clearance (<30, 30-50, >50 to 80, or >80 mL/minute); (iii) number of CDI episodes, inclusive of the qualifying episode (3 and ≥4); (iv) exposure to non-CDI-targeted antibiotics after dosing; and (v) acid-suppressing medication use at baseline. RESULTS: Of 281 participants screened, 182 were randomized (59.9% female; mean age, 65.5 years). Comorbidities were common with a mean overall baseline age-adjusted CCI score of 4.1 (4.1 in the VOS arm and 4.2 in the placebo arm). Across all subgroups analyzed, VOS-treated participants had a lower relative risk of recurrence compared with placebo. CONCLUSIONS: In this post hoc analysis, VOS reduced the risk of rCDI compared with placebo, regardless of baseline characteristics, concomitant medications, or comorbidities.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。